Bayer: creates new platform for cell and gene therapies
(CercleFinance.com) - Bayer is launching a new strategic platform to house its cell and gene therapy businesses, a move that the German drugmaker said will enable it to boost its presence in this area.
"The C> (cell and gene therapy) field is growing at an unprecedented pace," said Stefan Oelrich, member of Bayer's board of management and head of the pharmaceuticals division.
"It is our goal to be at the forefront of this revolution in science," he added.
Bayer said it plans to focus on stem cell therapies, gene augmentation, gene editing and allogeneic cell therapies in different indications.
Its pipeline already includes five advanced assets and over fifteen preclinical candidates, it said.
In addition, Bayer announced late on Tuesday a development and license deal with UK-based Blackford Analysis to create a digital platform for medical imaging.
The project will provide access to a marketplace through which healthcare professionals can centrally manage digital clinical imaging applications, including artificial intelligence (AI), the company said.
Copyright (c) 2020 CercleFinance.com. All rights reserved.
"The C> (cell and gene therapy) field is growing at an unprecedented pace," said Stefan Oelrich, member of Bayer's board of management and head of the pharmaceuticals division.
"It is our goal to be at the forefront of this revolution in science," he added.
Bayer said it plans to focus on stem cell therapies, gene augmentation, gene editing and allogeneic cell therapies in different indications.
Its pipeline already includes five advanced assets and over fifteen preclinical candidates, it said.
In addition, Bayer announced late on Tuesday a development and license deal with UK-based Blackford Analysis to create a digital platform for medical imaging.
The project will provide access to a marketplace through which healthcare professionals can centrally manage digital clinical imaging applications, including artificial intelligence (AI), the company said.
Copyright (c) 2020 CercleFinance.com. All rights reserved.